Bexxar - Tositumomab and iodine I 131 tositumoma - Glaxosmithkline/Corixa - New treatment for non-Hodgkin's lymphoma

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2003年 / 38卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：455 / 456
页数：2
相关论文
共 50 条
  • [1] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [2] Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL)
    Flowers, C. R.
    Sambrook, J. C.
    Briggs, A.
    Osenenko, K.
    Wang, H.
    Dalal, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Efficacy and safety of Bexxar® (tositumomab and iodine I 131 tositumomab) in obese patients with low-grade non-Hodgkin's lymphoma.
    Wahl, R
    Goldsmith, SJ
    Zasadny, KR
    Alavi, A
    Divgi, C
    Hankins, J
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
  • [4] Re-treatment with Tositumomab and Iodine I131 Tositumomab (the BEXXAR® therapeutic regimen) in patients with non-Hodgkin's lymphoma (NHL) with a previous response to the BEXXAR therapeutic regimen.
    Kaminski, MS
    Knox, SJ
    Radford, J
    Gregory, SA
    Leonard, JP
    BLOOD, 2003, 102 (11) : 407A - 407A
  • [5] Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members
    Rutar, FJ
    Augustine, SC
    Kaminski, MS
    Wahl, RL
    Siegel, JA
    Colcher, D
    CLINICAL LYMPHOMA, 2001, 2 (03): : 164 - 172
  • [6] Iodine-131 tositumomab (Bexxar) for treatment of lymphoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1168): : 86 - 87
  • [7] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [8] Bexxar® (tositumomab and iodine I 131 tositumomab) is well tolerated and efficacious in heavily pretreated patients with non-Hodgkin's lymphoma (NHL) and mild thrombocytopenia.
    Goldsmith, SJ
    Kostakoglu, L
    Wahl, R
    Alavi, A
    Divgi, C
    Hankins, J
    Zelenetz, A
    Kaminski, M
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 33P - 34P
  • [9] Bexxar™ (Iodine-131 tositumomab) radio immunotherapy for patients with B-cell non-Hodgkin's lymphoma
    Micallef, I
    Radford, J
    Britten, K
    Owen, S
    Deakin, D
    Jan, H
    Foley, R
    Barlow, R
    Carrington, B
    Lawrance, J
    Vinnicombe, S
    Harris, M
    Norton, A
    Lister, A
    Rohatiner, A
    BRITISH JOURNAL OF CANCER, 2000, 83 : 16 - 16
  • [10] Characteristics of patients with relapsed and refractory low grade non-hodgkin's lymphoma who sustained durable responses following treatment with tositumomab and iodine I 131 tositumomab (Bexxar®).
    Gregory, SA
    Kaminski, MS
    Zelenetz, AD
    Jain, V
    BLOOD, 2002, 100 (11) : 312B - 312B
12345